- Home
- ETNB vs CVAC Comparison
ETNB vs CVAC Comparison
Compare ETNB & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETNB
- CVAC
- Stock Information
- Founded
- ETNB 2018
- CVAC 2000
- Country
- ETNB United States
- CVAC Germany
- Employees
- ETNB N/A
- CVAC N/A
- Industry
- ETNB Biotechnology: Pharmaceutical Preparations
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- ETNB Health Care
- CVAC Health Care
- Exchange
- ETNB Nasdaq
- CVAC Nasdaq
- Market Cap
- ETNB 1.5B
- CVAC 1.2B
- IPO Year
- ETNB 2019
- CVAC 2020
- Fundamental
- Price
- ETNB $8.08
- CVAC $5.36
- Analyst Decision
- ETNB Strong Buy
- CVAC Hold
- Analyst Count
- ETNB 10
- CVAC 3
- Target Price
- ETNB $27.22
- CVAC $6.83
- AVG Volume (30 Days)
- ETNB 1.3M
- CVAC 475.8K
- Earning Date
- ETNB 11-06-2025
- CVAC 11-11-2025
- Dividend Yield
- ETNB N/A
- CVAC N/A
- EPS Growth
- ETNB N/A
- CVAC N/A
- EPS
- ETNB N/A
- CVAC 1.01
- Revenue
- ETNB N/A
- CVAC $599,540,810.00
- Revenue This Year
- ETNB N/A
- CVAC N/A
- Revenue Next Year
- ETNB N/A
- CVAC $23.95
- P/E Ratio
- ETNB N/A
- CVAC $5.32
- Revenue Growth
- ETNB N/A
- CVAC 675.15
- 52 Week Low
- ETNB $4.16
- CVAC $2.37
- 52 Week High
- ETNB $11.84
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- ETNB 35.99
- CVAC 46.28
- Support Level
- ETNB $7.84
- CVAC $5.32
- Resistance Level
- ETNB $9.47
- CVAC $5.41
- Average True Range (ATR)
- ETNB 0.45
- CVAC 0.04
- MACD
- ETNB -0.08
- CVAC -0.00
- Stochastic Oscillator
- ETNB 13.96
- CVAC 44.44
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.